INTRODUCTION
Major progress over the past decade in the treatment of lymphoid malignancies has resulted from the availability of safe and effective monoclonal antibodies. Rituximab in combination with chemotherapy has improved response rates and survival of patients with follicular non-Hodgkin's lymphoma (NHL) 1-3 and diffuse large B-cell lymphoma, 4-7 and historical comparisons suggest a prolongation of survival in chronic lymphocytic leukemia (CLL) as well. 8, 9 Immunomodulatory agents thalidomide and lenalidomide have changed the treatment approach for patients with multiple myeloma (MM) . Lenalidomide has also demonstrated activity in CLL and various histologies of NHL. 10 Other targeted drugs with impressive activity include the proteasome inhibitor bortezomib, which is approved for the treatment of multiple myeloma and mantlecell lymphoma. 11 Nevertheless, patients with indolent lymphoid malignancies, such as follicular lymphoma and CLL/ small lymphocytic lymphoma (SLL), or with MM invariably relapse and require a succession of treatments. Moreover, a substantial proportion of patients with the potentially curable diffuse large B-cell lymphoma are either refractory to or relapse after chemoimmunotherapy. Whereas high-dose chemotherapy with stem-cell transplantation is beneficial for select patients, additional effective salvage approaches are needed.
AN OLD DRUG REDISCOVERED
Bendamustine was first synthesized in the early 1960s at the Institute for Microbiology and Experimental Therapy in Jena, in the former East German Democratic Republic (GDR) by Ozegowski et al. 12 The intention was to synthesize a nitrogenmustard compound that was less toxic than, but at least as effective as, other alkylating agents. By relocating the nitrogen-mustard group to position 5 on a benzimidazole ring, they developed a compound with the chemical name ␥-[1-methyl-5-bis(␤-chloroethyl)-amino-benzimidazolyl-2]-butyric acid hydrochloride. Bendamustine has structural similarities to both alkylating agents and purine analogs (Fig 1) . The benzimidazole ring system may confer nucleoside-like properties and provides stability, allowing for longer-lasting DNA damage. 13 Initially, the compound was identified by the code IMET3393, but later it was called bendamustine. 12, 14 Strumberg et al 15 demonstrated incomplete cross-resistance between bendamustine and other alkylating agents (eg, cyclophosphamide, melphalan, carmustine) because of a substance-specific interaction between bendamustine and DNA. Bendamustine may also be associated with a relatively slower repair of DNA damage than with other alkylating agents, and may be more stable than other nitrogen mustards, including cyclophosphamide and chlorambucil.
Bendamustine does not show cross-resistance with other cytotoxic drugs, and is active in primary NHL cells refractory to conventional chemotherapeutic agents such as cyclophosphamide, doxorubicin, and etoposide. 13, 16 Using the National Cancer Institute's COMPARE analysis, Leoni et al 13 demonstrated that cyclophosphamide, chlorambucil, and melphalan exhibited a high degree of correlation, whereas the sensitivity pattern of bendamustine did not correlate with any other agent tested, suggesting a different mechanistic profile. Leoni et al exposed primary NHL lymphocytes from patients refractory to chemotherapy to various concentrations of bendamustine and a fixed dose of cyclophosphamide. 16 While high concentrations of bendamustine (200 mol/L) resulted in near 100% growth inhibition, 20 mol/L still resulted in more than 40% growth inhibition. In contrast to cyclophosphamide, bendamustine demonstrated activity against all samples, including those that were cyclophosphamide resistant. Most recently, bendamustine has been shown to differ from other alkylating agents by activation of DNA-damage stress responses and apoptosis, inhibition of mitotic checkpoints, induction of mitotic catastrophe, and activation of a base excisions DNA repair pathway rather than an alkyltransferase DNA repair mechanism. 13 Treatment of lymphoma cells with bendamustine initiates a p53-dependent stress pathway resulting in activation of intrinsic apoptosis, with an increase in Bax protein expression. Bendamustine also downregulated genes important in mitotic checkpoint regulation. The unique structure of bendamustine, and these observations, suggest that bendamustine has the potential for activity in patients with lymphoma relapsing after or resistant to alkylating agent-based therapy.
Chow et al 17 studied lymphoma cell lines in vitro and in ex vivo cells from patients with leukemic progression of lymphoma to clarify interactions between bendamustine and other chemotherapeutic agents. Antagonism was observed with mitoxantrone and doxorubicin, whereas bendamustine and cladribine exhibited in vitro synergy.
Synergism between bendamustine and rituximab was demonstrated in severe combined immunodeficiency mice with Daudi xenografts, 18 while adding rituximab reduces the dose of bendamustine required to induce apoptosis in CD20-positive DOHH-2 and WSU-NHL cell lines and ex vivo B-cell CLL cells. 19 These preclinical observations supported clinical studies combining the two agents.
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CLINICAL STUDIES
For over 30 years, bendamustine was used in the former German Democratic Republic as monotherapy in NHL, CLL, MM, Hodgkin's lymphoma, and breast cancer. Unfortunately, few validated study results exist from this early period. Following the German reunification, bendamustine was approved for the treatment of patients with indolent NHL, CLL, MM (Table 1) , and breast cancer, and study groups began to initiate trials of bendamustine to assess its value in these cancers.
Phase I and Pharmacokinetics
Bendamustine is primarily metabolized to mono-and dihydroxy metabolites, with a gamma-OH-bendamustine and N-desmethylbendamustine with cytotoxic activity formed by the CYP1A2 oxidative pathway. , with no evidence for dose dependency. The amount detected in the urine was highly variable. The pharmacokinetic profile (PK) of bendamustine administered on days 1 and 2 every 3 weeks produced virtually identical results, suggesting a lack of schedule dependency. 28 Owen et al 29 conducted a population pharmacokinetic analysis of bendamustine in patients with indolent NHL treated with 120 mg/m 2 day 1 and 2 every 3 weeks. Plasma concentrations declined in a triphasic manner, with a rapid distribution phase, an intermediate phase, and a terminal decline. They determined the intermediate terminal half-life of 40 minutes to be the most pharmacologically relevant since the initial phases accounted for 99% of the bendamustine area under the curve. Maximum serum concentration was 6 g/mL. Accumulation was not expected; thus, single-dose PK reflected multidosing schedules. Of interest was that neither mild to moderate renal nor mild liver impairment altered pharmacokinetics. 
Chronic Lymphocytic Leukemia
Phase II studies from East Germany using empiric dosing in relatively small numbers of patients with CLL provided evidence that bendamustine was effective with response rates of 65% to 93%, with a favorable safety profile 30-33 (Table 1) . In a recent European Intergroup CLL Study, 305 previously untreated CLL patients under 75 years of age and requiring therapy were randomized to bendamustine 100 mg/m 2 intravenously for 2 consecutive days or oral chlorambucil 0.8 mg/kg on days 1 and 15 of each cycle. 34 The median age was 65 years; 70% had Binet stage B and 30% stage C disease. Overall response rates (ORR) in 156 bendamustine-and 149 chlorambucil-treated patients were 68% (30% complete remission [CR] ) and 39% (2% CR), respectively (P Ͻ .0001). Corresponding ORRs by Binet stage B or C were 70% (34% CR) and 61% (22% CR), respectively, for bendamustine, and 47% (3% CR) and 22% (0% CR), respectively, for chlorambucil. Median progression-free survival (PFS) was 21.7 months versus 9.3 months for bendamustine and chlorambucil, respectively (P Ͻ .0001). Median duration of remission was 18.9 months for bendamustine and 6.1 months for chlorambucil (log-rank, stratified for Binet B/C, P Ͻ .0001). Nausea and vomiting were only modest with bendamustine, and there was no alopecia. The incidence of grade 3 to 4 infection was similar (5.8% for bendamustine, 3.5% for chlorambucil). These results led to the recent approval in the United States for bendamustine in CLL.
Encouraged by preclinical data and results with fludarabine and rituximab (F-R) alone or with cyclophosphamide, 9,35 the German CLL Study Group (GCLLSG) initiated the CLL2M phase II study to investigate the combination of bendamustine at 70 mg/m 2 on Abbreviations: PFS, progression-free survival; TTP, time to progression; OS, overall survival; CR, complete remission; CLL, chronic lymphocytic leukemia; TTF, time to treatment failure; B, bendamustine; Mitox, mitoxantrone; R, rituximab; NHL, non-Hopkin's lymphoma; F, fludarabine; MC, mantle-cell lymphoma; V, vincristine; P, prednisone or prednisolone; C, cyclophosphamide; CRu, complete remission, unconfirmed; M, melphalan; BO, bortezomib; Dex, dexamethasone; Clb, chlorambucil.
2 consecutive days plus rituximab (B-R) on day 1, at a dose of 375 mg/m 2 for the first course and 500 mg/m 2 during subsequent cycles in 81 relapsed CLL patients. 36 Median patient age was 66 years, with a median of two prior therapies. In the first 31 patients evaluable for response, the ORR was 65%, including 13% CRs. However, there were no molecular remissions by flow cytometry. The main adverse effects were reversible myelosuppression with 48 grade 3 to 4 adverse events including anemia in 6.3% of courses, lymphopenia/neutropenia in 10.8%, and thrombocytopenia in 11.9%. Three patients died due to infection (two pneumonias, one urosepsis). A phase III study comparing B-R with a regimen of fludarabine, cyclophosphamide, and rituximab in patients with untreated CLL will be activated in 2008 by the GCLLSG.
As a result of a phase I trial, Lissichkov et al 30 recommended a dose of 100 mg/m 2 for relapsed and refractory patients with CLL. However, the GCLLSG has recommended 70 mg/m 2 administered on days 1 and 2 every 4 weeks for relapsed patients either as a single agent 37 or in combination with rituximab. 36 One possible reason for the lower dose in the latter series was that some patients had previously received fludarabine and, therefore, may have had more compromised bone marrow reserves. 37 The recommended dose of bendamustine for previously untreated patients with CLL is 100 mg/m 2 on days 1 and 2 every 4 weeks.
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Indolent Non-Hodgkin's Lymphomas Initial studies from the German Democratic Republic stimulated further interest in pursuing bendamustine in indolent NHL (Table 1) . Heider and Niederle 38 administered bendamustine at 120 mg/m 2 on 2 successive days every 3 weeks to 52 patients with relapsed or refractory indolent lymphomas. The ORR was 73%, including 6 CRs (11%). Median duration of remission was 16 months. Bremer 31 administered 60 mg/m 2 /d for 5 consecutive days to 102 patients with a variety of lymphoid malignancies, including 46 with lymphoplasmacytic lymphoma, and reported a response rate of 82%, with 15% CRs.
Based on the encouraging German studies, two single-agent phase II trials were conducted in the United States. Friedberg et al 39 reported 76 patients with relapsed or refractory indolent and transformed NHL who were refractory to rituximab, defined as progressing within 6 months of the first dose of rituximab, rituximab maintenance, or chemotherapy plus rituximab. Bendamustine 120 mg/m 2 was administered on days 1 and 2 every 21 days for six to 12 cycles. Thirty-four patients received at least six cycles of treatment. The median age was 63 years, 61% had follicular lymphoma, 19% had transformed to an aggressive histology, and 88% had stage III or IV disease. Patients had received a median of two prior regimens (range, one to five priors). The Follicular Lymphoma International Prognostic Index categories for the 46 patients with follicular NHL were low-(26%), intermediate-(30%), and high-risk (33%), with 11% unknown. Of 74 evaluable patients, the ORR was 77%, including 34% CR and unconfirmed CR (CRu). Non-cross-resistance to alkylating agents was supported by the ORR of 61% (including 13% CR) in alkylator-refractory patients. PFS was 7.1 months; 8.3 months for the indolent histologies and 4.2 months for the transformed NHL. The median duration of response for all patients was 6.7 months, 9 months for those with an indolent histology and 2.3 months for those with transformed disease; 33% of the patients with indolent disease remained disease-free at 2 years (Fig 2) .
These data were confirmed in the pivotal trial reported by Kahl et al, 40 conducted in the United States and Canada in 100 patients with rituximab-refractory, indolent NHL. Bendamustine was administered at 120 mg/m 2 on days 1 and 2 every 21 days for six to eight cycles. Histologies included follicular NHL (62%), CLL/SLL (26%), and marginal-zone NHL (21%); 76% had stage III-IV disease. Patients received a median of three prior regimens, including two prior rituximab-containing regimens; 37% had received prior nucleoside analog therapy; 24% prior radioimmunotherapy; and 36% were refractory to the last prior chemotherapy. The ORR of 84% including 32% CR and CRu confirmed the prior phase II trial. 39 The median response duration was 9.3 months and the median PFS was 9.7 months.
These studies demonstrate that bendamustine is highly active in rituximab-refractory patients. Response rates are at least comparable with I
131
-tositumomab or Y 90 -ibritumomab in relapsed or refractory follicular and low-grade NHL, the only agents currently approved for this indication.
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Several combinations incorporating bendamustine have been evaluated. Herold et al 43 compared a more intensive bendamustine schedule (60 mg/m 2 daily for 5 days) with vincristine and prednisone (BOP) with cyclophosphamide (400 mg/m 2 /d for 5 days), vincristine and prednisone (COP); a second randomization between interferon maintenance therapy and observation complicates interpretation of the study. In 164 previously untreated patients with stages III and IV follicular lymphoma, immunocytoma, or mantle-cell lymphoma, response rates were similar with BOP (ORR 66%; CR 22%) and COP (ORR 76%; CR 20%). The projected 5-year survival rate was 61% with BOP and 46% with COP, and the median overall survival was 76 months for BOP and 54 months for COP (P ϭ .2). However, a projected 5-year survival advantage for BOP was observed for responding patients, 74% versus 56% (P ϭ .05). The 5-year event-free survival rate among responding patients who did not receive interferon maintenance was 69.7% and 47% in BOP-and COP-treated patients, respectively (P ϭ .03). BOP was better tolerated with a lower incidence of grade 3 to 4 leukopenia (19% v 34%, P Ͻ .0001).
Weide et al 44 treated 57 patients with relapsed or refractory indolent (n ϭ 39) and mantle-cell lymphomas (n ϭ 18) using bendamustine, mitoxantrone, and rituximab. An ORR of 89% was achieved, with 35% CRs. The estimated median PFS was 19 months. Mitoxantrone did not appear to add to the expected efficacy of the combination of B-R, 20 but increased hematotoxicity with WHO grade 3 and 
Fig 2.
Duration of response (DR) in months (mos) for all bendamustine-treated patients (n ϭ 76), patients with indolent disease (n ϭ 61), and patients with transformed (n ϭ 15) disease. 37 Reprinted with permission.
4 leukopenia in 78% of cases. 44 Similarly, the combination of fludarabine with bendamustine was not superior to what would have been expected with bendamustine alone.
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Bendamustine in Combination With Rituximab
Bendamustine (90 mg/m 2 on days 1 and 2) plus rituximab (375 mg/m 2 ) was first studied by the Study Group indolent Lymphomas (StiL) in 63 patients with relapsed or refractory lymphomas (median age, 63 years). 20 Histologies included follicular lymphoma (n ϭ 24), mantle-cell lymphoma (n ϭ 16), immunocytoma (n ϭ 17), and marginal-zone lymphoma (n ϭ 6). One third of patients were refractory to their last treatment, mainly a regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Prior treatment with rituximab was excluded. B-R was administered every 4 weeks for up to four cycles. Additional doses of rituximab were administered 1 week before the first cycle and 4 weeks after the last cycle. Forty-three, 12, and eight patients had received one, two, or three prior treatments, respectively. ORR was 90%, including 60% CRs. Among the 16 patients with mantle-cell lymphoma, of whom seven were resistant to their last treatment, remission was achieved in 75%, with 50% CRs. All 17 patients with lymphoplasmacytic lymphoma responded. The median PFS for all patients was 24 months (5 to Ն 44 months). The probability of survival after 4 years was 55%. Hematological toxicity included grade 3 or 4 leukopenia (16% of cycles), thrombocytopenia (3% of cycles), and anemia (1% of cycles). No organ toxicity was reported.
These data have been confirmed by a US multicenter trial reported by Robinson et al 21 in patients with follicular, low-grade, and mantle-cell NHL relapsing after chemotherapy with or without rituximab, but not rituximab-refractory NHL. The regimen included bendamustine 90 mg/m 2 on days 2 and 3 every 28 days, with rituximab 375 mg/m 2 on day 1 of each cycle to replicate the regimen of Rummel et al. 20 Median age was 60 years, and 82% had stage III or IV disease. Most patients had an indolent histology (82%) including 61% follicular NHL, 15% CLL/SLL, 3% lymphoplasmacytic lymphoma, 3% marginal zone NHL, and 18% mantle-cell lymphoma. The Follicular Lymphoma International Prognostic Index score for the 40 patients with a follicular histology was evenly distributed between risk groups. Prior therapies included rituximab in 56% of patients. ORR was 92% including 55% CR and CRu with no difference between patients with indolent and mantle-cell histologies or by the number of prior regimens (one v Ͼ one). The ORR was lower in patients who received prior rituximab (86%, with 35% CRs), but the difference was not significant. The PFS was similar between mantle-cell and indolent histologies, number of prior regimens, or prior rituximab therapy (Fig 3) .
On the basis of these results, the StiL initiated two prospective, randomized, phase III studies comparing B-R with two standard therapeutic regimens. In the first, B-R was compared with a regimen of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line therapy in patients with indolent and mantle-cell NHL. 46 In a preliminary analysis of 315 evaluable patients, ORR were 93% for both arms, with CRs in 47% and 42% for B-R and R-CHOP, respectively. At a median follow-up of 18 months, PFS was comparable (not yet reached for B-R v 39 months for R-CHOP [P ϭ .11]), and overall survival was similar. Toxicity favored B-R, with 0% versus 94% alopecia and 16% versus 41% grade 3 or 4 leukopenia. A comparison of B-R with F-R in relapsed/refractory patients with indolent NHL is ongoing. Combinations of bendamustine and rituximab with other drugs are being studied.
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Aggressive Non-Hodgkin's Lymphomas Limited data suggest activity for bendamustine against aggressive lymphomas (Table 1) . Weidmann et al 48 administered bendamustine 120 mg/m 2 on days 1 and 2 every 3 weeks to 18 patients (median age, 66 years) who had relapsed or were resistant to their previous treatment and not considered candidates for autologous stem-cell transplantation. Eight patients (44%) responded with three CRs (17%). The CRs lasted 6, 8ϩ, and 27ϩ months, compared with only 2, 3, and 10 months for the partial remissions.
Friedberg et al 39 reported 15 patients with indolent NHL that had transformed to an aggressive NHL. The ORR (66%) was lower than with follicular lymphoma (81%), and the median PFSs were 4.2 months and 8.3, respectively.
Multiple Myeloma
Bendamustine is also active in patients with MM 49,50 (Table 1) . Pö-nisch et al 49 randomly assigned 131 patients to bendamustine (150 mg/m 2 days 1 and 2) or melphalan (15 mg/m 2 day 1) every 4 weeks; both arms received prednisolone (60 mg/m 2 daily on day 1 through 4). Cross-over was permitted within 3 months for progression. The ORR was 75% for the bendamustine-prednisolone arm and 70% for melphalan-prednisolone. However, bendamustine achieved CRs in 32% compared with 13% with melphalan (P ϭ .007), with a shorter time to maximum response with bendamustine: 6.8 cycles for bendamustine-prednisolone, but 8.6 cycles with melphalanprednisolone (P Ͻ .02). Time-to-treatment failure was longer for bendamustine at 14 months compared with 10 months for melphalan (P Ͻ .02), with no difference in overall survival. The toxicities of the two arms were comparable. Further evaluation of bendamustine in MM appears warranted and it is currently being tested in combination with new, active agents, such as bortezomib. 51, 52 Bendamustine in Other Malignancies Based on a single study, 53 bendamustine does not appear to be effective in acute myelogenous leukemia or myelodysplastic syndrome. Activity has been reported in breast and small-cell lung cancer and sarcoma, but not melanoma, germ cell tumors, hepatocellular or bile duct cancers, or head and neck cancer (Table 2) . 
TOXICITY OF BENDAMUSTINE
In general, bendamustine is well-tolerated. Friedberg et al 39 reported that 47% of patients experienced grade 3 to 4 neutropenia, but only 7% had febrile neutropenia. Grade 3 to 4 thrombocytopenia and grade 3 anemia were reported in 24% and 9% of patients, respectively. The most common nonhematologic toxicities included nausea, fatigue, vomiting, fever, diarrhea, and constipation, almost all mild to moderate in severity. An infusion reaction syndrome in seven patients was characterized by fevers, hypotension, back and muscle pain, chills, and rigors within 24 hours of administration of the drug, up to the third cycle. Three patients also experienced a transient elevation in serum creatinine. The syndrome resolved with discontinuation of the drug or with the introduction of corticosteroids. Kahl et al 40 reported that 24% of patients had dose reductions due to adverse events, primarily neutropenia and thrombocytopenia, although the relative dose intensity was 88%. Grade 3 to 4 neutropenia occurred in 61% of patients, leading to filgrastim use in 38% of patients. Grade 3 to 4 thrombocytopenia in 25% of patients was the most common reason for premature treatment discontinuation (9%). Infections of any grade were recorded in 69 patients. Seven fatal adverse events were thought to be possibly drug-related, including cytomegalovirus pneumonia and three other pneumonias with respiratory failure or sepsis. Infusion reactions were mild and uncommon.
Because bendamustine is an alkylating agent, secondary malignancies are a potential concern. Friedberg et al 39 noted two patients with myelodysplastic syndrome and one with chronic myelomonocytic leukemia, all heavily pretreated. Kahl et al 40 reported a patient who developed myelodysplastic syndrome and another with a squamous cell carcinoma. Future studies should monitor patients closely for these complications.
CONCLUSION
Recently completed trials in the United States and Europe have confirmed the efficacy and safety of bendamustine as a single agent or in combination with rituximab in follicular, low-grade, and mantle-cell lymphoma. This drug was approved for CLL and rituximab-refractory indolent lymphoma in the United States and for CLL, NHL, and MM in Germany. The relative tolerability of bendamustine provides a favorable treatment option for patients with CLL and NHL in general, and may be a preferred option for elderly patients, those with comorbidities, and patients with CLL who are not considered suitable candidates for more immunosuppressive agents such as alemtuzumab. Because of the possibility of nausea and vomiting, prophylactic antiemetics should be routinely used. The risk of infection with bendamustine does not appear to be increased over other chemotherapy regimens, thus prophylactic antimicrobials are not indicated. Whether bendamustine is immunosuppressive has not been determined, and the depth and duration of myelosuppression needs to be better characterized. As bendamustine is more widely used, less common toxicities may be encountered and should be reported.
Despite the lengthy history of this agent, a number of important questions remain unanswered. The precise mechanism of action and of resistance needs to be clarified. The optimal dose and schedule have yet to be determined. In various studies in CLL or NHL, doses have ranged from 100 mg/m 2 to 120 mg/m 2 as a single agent, and 70 mg/m 2 to 90 mg/m 2 when combined with rituximab, varying from every 3 weeks to every 4 weeks. It has also been given weekly to women with advanced breast cancer. 54 However, phase I studies in solid tumors have recommended doses ranging from 60 mg/m 2 weekly 25 to 150 mg/m 2 on 2 consecutive days every 3 weeks. 28 Pharmacokinetic data on which to base scheduling strategies are lacking.
Different doses may be required for different patient populations, and the optimal dose has not yet been defined. For example, the dose supporting the US Food and Drug Administration approval for NHL is 120 mg/m 2 on days 1 and 2 every 3 weeks, which may be too intensive for elderly or heavily pretreated patients. The current recommendation is to use the drug with caution in patients with mild to moderate renal or hepatic impairment, but not with a creatinine clearance less than 40 mL/min or with an AST or ALT more than 2.5 times or bilirubin more than three times the upper limit of normal.
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Patients with more severe dysfunction have not been studied and optimal dosing strategies are needed.
Bendamustine is superior to chlorambucil in CLL, 34 and therefore is a reasonable initial treatment option, especially for patients not considered candidates for fludarabine-based regimens, such as the elderly or those with comorbidities. Results of ongoing studies comparing bendamustine with fludarabine may alter current treatment patterns. The activity of bendamustine will likely be enhanced by the addition of rituximab. Bendamustine provides an option for patients with CLL not suitable for alemtuzumab because of bulky lymph nodes or a history of recurrent infections. Clinical trials are needed to define the efficacy of this agent compared with more effective, standard regimens such as F-R alone or with cyclophosphamide, and its role in patients who have failed these regimens needs to be determined.
Bendamustine has the potential to play an important role in patients with indolent NHL due to reported response rates of over 70% in rituximab-refractory patients, 39, 40 which are comparable to radioimmunotherapy 41, 42 ; thus, bendamustine would be a suitable alternative for patients not candidates for radioimmunotherapy because of bone marrow involvement or other contraindications. With the favorable results of B-R compared with R-CHOP in first-line therapy, 46 the former could be a reasonable alternative in older patients, or those with cardiac impairment; longer follow-up is needed before B-R can replace R-CHOP in younger patients. Based on its response rates, bendamustine could be considered an effective alternative to a regimen of rituximab plus cyclophosphamide, vincristine, and prednisone.
Bendamustine may also play a role in aggressive histologies. The reported 92% ORR with 59% CRs and a median duration of response of 19 months in patients with relapsed or refractory mantle-cell lymphoma 21 compares favorably to the 33% ORR with 8% complete remissions and a median time to progression of 6.2 months with bortezomib, the only drug approved for this indication. 11 Weidmann et al 48 reported 44% responses for bendamustine in relapsed aggressive NHL. Given the lack of effective options for this group of patients, bendamustine-based regimens should be studied. In addition, the role of bendamustine in T-cell NHL and Hodgkin's lymphoma remains to be evaluated.
Sequencing issues also need to be considered. Bendamustine is active in patients for whom alkylating agents or fludarabine have failed (Kahl et al, manuscript submitted for publication). 39 However, whether these drugs will be effective and tolerated following bendamustine has not been evaluated.
The greatest potential for bendamustine will likely be in combination with other agents such as monoclonal antibodies, lenalidomide, and bortezomib. A phase I trial of bendamustine, lenalidomide, and rituximab in CLL and NHL currently underway will provide the doses for future phase II and III trials (B. Cheson, personal communication, January 2009). A multicenter phase I/II trial of bendamustine with bortezomib and rituximab is accruing patients with relapsed and refractory follicular and transformed NHL. Ongoing phase III trials of the StiL in Germany of B-R versus R-CHOP and B-R versus F-R will further define the role of bendamustine in indolent and mantle-cell lymphomas relative to current standard approaches.
In summary, bendamustine is a novel agent with significant activity, especially in patients with lymphoid malignancies. Rational development of bendamustine-based combinations will likely improve the outcome of patients with lymphomas and CLL. 
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